Lawrence Evans
About Lawrence Evans
Lawrence Evans serves as the Director of Research at Alpine Immune Sciences, Inc., where he has worked since 2015. He has extensive experience in developing therapeutic candidates for autoimmune and oncology applications, previously holding positions at Amgen for nearly a decade.
Work at Alpine Immune Sciences
Lawrence Evans has served as the Director of Research at Alpine Immune Sciences, Inc. since 2015. In this role, he has focused on identifying clinical candidate leads with affinity against various immunoglobulin superfamily (IgSF) and tumor necrosis factor receptor superfamily (TNFRSF) therapeutic targets. His work primarily addresses applications in autoimmune diseases and oncology. Evans has contributed to the advancement of several therapeutic candidates, enhancing the company's research portfolio.
Previous Experience at Amgen
Prior to his current position, Lawrence Evans worked at Amgen for a total of nine years, from 2005 to 2014. He held roles as Senior Associate Scientist and later as Scientist in the Department of Oncology and Inflammation. During his tenure, he led the development of a primary B cell assay for ALPN-303, which was crucial for demonstrating the effects of APRIL and BAFF inhibition. His work contributed to clinical trials targeting autoimmune kidney diseases and autoimmune cytopenias.
Education and Expertise
Lawrence Evans earned a Bachelor of Science degree in Microbiology and Molecular Biology from Washington State University. His academic background has provided him with a strong foundation in the biological sciences, which he has applied throughout his career in immunology and oncology research. His expertise includes the development of assays to monitor the binding and activity of affinity matured proteins, as well as contributions to IND-enabling studies.
Contributions to Drug Development
Throughout his career, Lawrence Evans has played a significant role in the development of therapeutic candidates. At Alpine Immune Sciences, he contributed to the development of ALPN-101, a dual ICOS and CD28 inhibitor, which is currently in Phase 2 clinical trials for systemic lupus erythematosus (SLE) in collaboration with AbbVie Inc. His work has included lead identification and the development of assays for drug qualification and release, demonstrating his impact on advancing drug candidates through the research pipeline.